OBI — Ondine Biomedical Share Price
Last trade - 00:00- £17.68m
- £17.19m
- CA$1.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1,656.03 | ||
| Price to Tang. Book | 1,656.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.26 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76868.42% | ||
| Return on Equity | -685.59% | ||
| Operating Margin | -893.82% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.58 | 0.45 | 2.57 | 0.64 | 1.2 | n/a | n/a | 5.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
Directors
- Jean Charest CHM
- Nicolas Loebel PRE
- Carolyn Cross CEO
- Cameron Lawrence CFO (40)
- Thomas Dawson VOP
- Merrill Biel DRC
- Junaid Bajwa NED
- Mike Farrar NED
- Simon Sinclair NED
- Craig Tooman NED (55)
- Michael Crane IND
- Margaret Shaw IND (57)
- Colin Watt IND
- Jean Duvall NID
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 9th, 1996
- Public Since
- December 6th, 2021
- No. of Employees
- 43
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 277,285,759
- Address
- 888-1100 Melville St, VANCOUVER, V6E 4A6
- Web
- https://ondinebio.com/
- Phone
- +1 6046690555
- Auditors
- PricewaterhouseCoopers LLP
Latest News for OBI
Upcoming Events for OBI
Similar to OBI
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 22:26 UTC, shares in Ondine Biomedical are trading at 6.38p. This share price information is delayed by 15 minutes.
Shares in Ondine Biomedical last closed at 6.38p and the price had moved by -22.73% over the past 365 days. In terms of relative price strength the Ondine Biomedical share price has underperformed the FTSE All Share Index by -30.78% over the past year.
There is no consensus recommendation for this security.
Find out moreOndine Biomedical does not currently pay a dividend.
Ondine Biomedical does not currently pay a dividend.
Ondine Biomedical does not currently pay a dividend.
To buy shares in Ondine Biomedical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 6.38p, shares in Ondine Biomedical had a market capitalisation of £17.68m.
Here are the trading details for Ondine Biomedical:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: OBI
Based on an overall assessment of its quality, value and momentum Ondine Biomedical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ondine Biomedical. Over the past six months, its share price has underperformed the FTSE All Share Index by -15.84%.
As of the last closing price of 6.38p, shares in Ondine Biomedical were trading -21.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ondine Biomedical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 6.38p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ondine Biomedical's management team is headed by:
- Jean Charest - CHM
- Nicolas Loebel - PRE
- Carolyn Cross - CEO
- Cameron Lawrence - CFO
- Thomas Dawson - VOP
- Merrill Biel - DRC
- Junaid Bajwa - NED
- Mike Farrar - NED
- Simon Sinclair - NED
- Craig Tooman - NED
- Michael Crane - IND
- Margaret Shaw - IND
- Colin Watt - IND
- Jean Duvall - NID